Featured Story

Benitec IPO swoons amid market rout, but other drug delivery focused players still trying to debut

Australia's RNA interference specialist Benitec Biopharma chose a bad week to debut on the Nasdaq. The company raised $14 million by offering 1.5 million American depositary shares on Aug. 18, but its stock was down 13% by Friday, a week which saw the Nasdaq Biotechnology Index fall 4.5%.

Copper naturally assembles in bio component to make stable, scalable delivery structures

A new copper-based biological nanomaterial discovered and assembled at Louisiana Tech University interacts with cells in the body and could ultimately be used as a targeted delivery tool to treat cancer and other diseases.

Study finds novel, rectal drug delivery catheter is useful in emergency settings

In November the federal National Science Foundation awarded a $700,000 research grant to Hospi so that it could expand use of the only FDA-cleared device for rectal delivery of medications. The early results look promising.

FDA grants fast track designation to oral formulation of intravenous antifungal agent

Matinas BioPharma's lead antifungal candidate (MAT2203) earned the FDA's fast track designation as a so-called Qualified Infectious Disease Product, demonstrating the agency's efforts to speed along medications for infectious diseases after years of industry under-investment in that arena. 

Edge files for up to $115M IPO to support locally delivered med for brain aneurysms

Edge Therapeutics is deploying drug delivery to improve the standard of care for treating ruptured brain aneurysms, and hopes to receive $115 million via an IPO on the Nasdaq, for which it just filed.


From Our Sister Sites


Engineer Scott Leibrand and diabetes patient Dana Lewis have created an artificial pancreas, via years of constant experimentation and iterative upgrades.


Insulet said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance. In July, the company issued a voluntary recall of more than 400,000 OmniPod Insulin Management Systems, which are wearable insulin pumps.